This study consisted of three back injury subjects, who used the DAVID Paradise to treat their chronic pain. They measured pain, medication used, suicide ideation, anxiety, self-esteem, hopefulness, coping ability and family stability. The results were very encouraging. One subject was taking up to 35 Extra Strength Tylenol with codeine per day before treatment and experiencing a subjective pain level of "7" out of "9". After one year of AVE, he was down to two or less Tylenol daily and reported a subjective pain level of "2."

This study used the DAVID Paradise to treat chronic pain. Of the twelve participants who completed the study, most had pain due to fibromyalgia, lupus, arthritis, TMJ Dysfunction and/or motor vehicle accidents. After eight weeks of treatment, the Visual Analogue Pain Scale showed a reduction in the pain to the p<0.005 level and the Beck Depression Index showed improvements to the p<0.05 level. This study shows the benefit of using AVE in the treatment of chronic pain. A subsequent study is currently in progress.

FMS is dominant primarily in women (3-5%). FMS is characterized by physical symptoms of muscle pain, chronic fatigue and non-restful (alpha) sleep. Most sufferers of FMS experience depression (>70%), anxiety (24%) and cognitive problems of "Fibro-fog" (a slow alpha brainwave condition).

Three groups totaling 49 participants were randomly selected and placed into an AVE, medical treatment or nutrition group. Participants were taken from Dr. Seibel's patient list. During the first month all participants received individual treatments and during the second month, received all treatments combined. Participants were assessed on a SCL-90 personality test. The AVE group showed better improvements than the medical and nutritional groups (see graph). Participants used the AVE as follows; 1) Delta stimulation at bedtime for sleep; 2) Alpha sessions in the afternoon - for anxiety, and; 3) Beta sessions upon awakening - for a clear mind.